The two $50,000 prizes are awarded to outstanding researchers focused on improving the lives of individuals with brain or heart disease. The recipients were chosen by an international panel of experts and a UBC committee chaired by Dr. Gavin Stuart, the Dean of the Faculty of Medicine and UBC's Vice Provost, Health.
The Margolese prizes were created by an estate gift to UBC by Leonard Hubert Margolese to recognize Canadians who have made outstanding contributions to the treatment, amelioration or cure of brain or heart disorders. Margolese, who died in 2000, was a Vancouver businessman who had a heart condition and whose brother had Alzheimer's disease.
Dr. Rouleau, winner of the Margolese National Brain Disorders Prize, is a Professor of Medicine, a Canada Research Chair in Genetics of the Nervous System, and Director of the Centre for Excellence in Neuroscience at the University of Montreal. He has focused on identifying the genes and mutations that play a role in neurological and psychiatric diseases, and understanding the molecular mechanisms that lead to these diseases.
Dr. Cairns, winner of the Margolese National Heart Disorders Prize, is a Professor in UBC's Division of Cardiology. He has focused on the causes and prevention of heart attacks, as well as the optimal management of patients who have experienced heart attacks. He proved, through a multi-centre clinical trial, that aspirin can reduce by more than half the incidence of heart attacks and death among patients with unstable angina (a loss of blood flow and oxygen to the heart). The finding revolutionized treatment of these at-risk individuals, shifting the focus toward limiting the growth of newly-formed clots in coronary arteries (those supplying the heart).
Dr. Rouleau and Dr. Cairns will be honoured at a banquet in the fall.
Dr. Guy Rouleau, winner of the Margolese National Brain Disorders Prize, has helped identify 20 disease-causing genes, including those that result in certain brain tumours, amyotrophic lateral sclerosis, forms of muscular dystrophy and juvenile epilepsy. He has proven that genetic mutations play a role in autism, schizophrenia, restless leg syndrome and Tourette syndrome (of which he is among the world's most cited authorities).
His work led to the development of diagnostic tests for several of these conditions, and laid the groundwork for future treatments. He has received $50 million in research grants over the past two decades, and his work, published in such prestigious journals as Nature, Nature Genetics, The Lancet, Cell, The New England Journal of Medicine and Science, has been cited over 28,000 times.
Dr. John Cairns, winner of the Margolese National Heart Disorders Prize, led the first clinical trial to prove the effectiveness of amiodarone, an anti-arrhythmia drug, in preventing sudden death in people who had already experienced a heart attack.
He has led or participated in the development of clinical practice guidelines in Canada and North America for the prevention and treatment of coronary blood clots and prevention of post-heart attack arrhythmias and atrial fibrillations (heart beats that are too fast or irregular). Currently, Dr. Cairns is the co-leader of the Canadian Network and Centre for Trials Internationally (CANNeCTIN), a collaborative national network and coordinating centre, jointly funded by Canadian Institutes of Health Research and Canada Foundation for Innovation, aimed at facilitating multi-centre studies in cardiovascular disease and diabetes.
As Dean of the Faculty of Medicine from 1996 to 2003, Dr. Cairns led the expansion of the Faculty of Medicine's medical education program, which involved the doubling of enrolment and the training of medical students throughout B.C.
Provided by University of British Columbia
This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.